Allergy Control Program

Transcription

1 Allergy Control Program Allergychoices, Inc.

2 Reversing a Mindset Immunotherapy First Line Treatment Treatment of Last Resort: Immunotherapy Disrupt the status quo.

3 The Allergy Epidemic: Hidden Costs ~60 million allergic Americans 20-30% of population suffer with allergies Triggers many other chronic conditions Direct & indirect costs continue to rise Leading medical cause of lost productivity #1 class, U.S. OTC medication, allergy related Growing problem, increasing prevalence

4 The Allergy Iceberg Allergic Rhinitis (50M) Chronic conditions highly correlated to Allergic Rhinitis: Asthma (25M) Sinusitis (29.4M) Eczema (31.6M) Anaphylaxis (6.6M) 100M Others we have found migraines, vaginitis, psoriasis, depression, anxiety

5 Direct cost of an allergy sufferer Chronic Care Management Issues Allergic Rhinitis Cost varies with severity $ /pt/yr, JACI Risk factor: heart disease, obesity, depression in kids, Chronic Sinusitis - $5560-$5955/pt/yr, JACI Food Allergy - $4184/child/yr (caregiver impact) Asthma - annual cost of care $3266/pt JACI Journal of Allergy and Clinical Immunology (primary periodical of allergists)

6

7 Employer Allergy Productivity Studies Current Medical Research Opinions, 2006 Jun;22(6): Study of 8267 US employees, 47 employer locations, 55% ee s w/ar, Sx avg 52.5 days/yr, 3.6 days absent, 2.3 hrs/day diminished Progressive Insurance, 2006 Cornell University Review, Presenteeism avg. 60% of total worker illness costs, allergies 80% Harvard Business Rev, 2004, $150B U.S. loss Hughes Electronics Study, % workers w/allergies avg 4 days of productivity loss ~ $900,000 Lockheed Martin 2002 study, ~60% employee w/allergy/sinus issues Employer Health Coalition (Tampa, FL) Presenteeism, 7.5x greater than Absenteeism costs Related consideration cost of increased on-the-job accidents 2007 Econtech Study, allergic disease cost Australian economy $250B Canadian Study, Asthmatics 31.4 days/yr of Major Activity Loss

8 Allergy prevalence increase over past 20 years increased medical expenses/lost productivity 338% and the trajectory isn t slowing *Fortune Magazine: 7/26/10

9 Further Complications Costs rising medications, procedures Fewer allergists/specialists treating allergy, especially its broader reach Allergic disease is on the rise System focused on symptom relief, not disease modification

10 Current Standards of Care Avoidance stay away from triggers Environmental controls Symptom Relief OTC and Prescription Medications Abound New pharma innovations (biologics) Results: Costs don t go away Disease can escalate into other comorbidities

11 Current Standards of Care Immunotherapy retrain the immune system The only disease-modifying approach ~5% of allergy sufferers receive treatment that changes the underlying disease Predominant Method, Allergy shots Safe and effective Challenge: Adherence (side effects, convenience) Inconsistency in use of diagnostic testing

12 Time to Expand the Standard: Sublingual Immunotherapy (SLIT) Precision Allergy Drops delivered to a privileged area (sublingual) under the tongue Disease modifying Same extracts as shots Proven effective route of delivery Builds long-term tolerance; typically 3-5 yrs. Safe, flexible for a broad range of patients/conditions Higher patient adherence Cost effective (50-75% lower)

13 Addresses Allergic Fingerprint the unique nature of allergy sufferers

14 An Optimized Approach The Allergy Control Program (ACP) La Crosse Method Protocol (LCM) Developed at Allergy Associates of La Crosse, La Crosse/Onalaska WI ~50 years of clinical use Evidence-based: US and International Research 38 publications on LCM Outcomes validated by the Validation Institute ,000 patients treated 2000 providers trained via Allergychoices

15 How Allergychoices ACP works Identify organization s Allergic footprint Code review Diagnostic & Procedures Extensive list of ICD10 - ID patients CPT codes to determine related procedures, comorbid conditions asthma, sinusitis, eczema, otitis media, respiratory infections, etc. Medication Use from PBM Extensive list of allergy (and related condition) meds OTC medications, largest category allergy related Allergy Specific Health Risk Assessment data Typically self-reported rates even higher morbidity

16 Allergychoices ACP Implementation Protocol training for diagnostics & treatment with key providers; onsite, near-site, DPC Pharmacy/lab integration Workflow with best practices integration Ongoing patient management/education with clinical support Adherence, education, support

17 The ACP Treatment Framework: Why it makes more sense for patients Treats each patient specifically at a therapeutic level for their unique allergic makeup Multiple allergens simultaneously; environmental and food Can reverse or lessen existing related co-morbidities Can prevent development of related chronic diseases Self-administered; take at home and on the go Reduces healthcare spending for employees and dependents on: Medication, unplanned visits/procedures, comorbidities Improves quality of life

18 The ACP Treatment Framework: Why it makes more sense for employers Reduces current healthcare spending for employees and dependents on: Medication, unplanned visits/procedures, comorbidities Reduces future healthcare spending Stops allergic march; prevent chronic disease escalation Improves organization productivity Employee health, wellness, quality of life, absenteeism & presenteeism Ideal lifestyle medicine approach Naturally occurring biologics, tailored to patient, convenient Integrates seamlessly with on- or near-site care models

19 Allergychoices Allergy Control Program Design hits the Triple Aim for Allergic Disease: Better Care Patient access & satisfaction through tools designed to fit employer needs Improve Health Meaningful results addressing disease source, QOL Lower Cost 50-75% lower than conventional allergy dx & tx IHI Triple Aim framework developed by Institute for Healthcare Improvement, Cambridge, MA

20 The Human Impact: Alex Schuman Drop by Drop, a documentary from journalist/allergy sufferer Alex Schuman, chronicles his experience searching for treatment, industry factors, provider interviews and stories from other patients who found help after learning about sublingual immunotherapy as a disease modifying option. Viewable on Amazon Prime: Morris/dp/B01M04G8VQ

21 Questions? Please direct questions to: Anne Hendrickson O: / C: Jeff Kessler C: